New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 18, 2014
18:21 EDTONTY, RAX, PDLI, URBN, SKH, WPX, AROOn The Fly: After Hours Movers
UP AFTER EARNINGS: PDL BioPharma (PDLI), up 4.2% after reporting second quarter results and announcing that the company delivered a notice of default to Wellstat Diagnostics. ALSO HIGHER: Aeropostale (ARO), up 4.9% after announcing CEO transition and issuing second quarter guidance... Skilled Healthcare (SKH), up 44.7% following Genesis HealthCare combination... Rackspace (RAX), up 3.1% after Blue Harbour reported a 6.4% stake in the company... WPX Energy (WPX), up 1.2% after announcing announcing sale of mature coalbed methane holdings in the Powder River Basin. DOWN AFTER EARNINGS: Urban Outfitters (URBN), down 1.7%. ALSO LOWER: Oncothyreon (ONTY), down 8.3% after announcing that EMR 63325-009 study did not its meet primary endpoint.
News For PDLI;ARO;SKH;RAX;WPX;URBN;ONTY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
10:02 EDTURBNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:46 EDTRAXRackspace volatility elevated into Q2 and outlook
Subscribe for More Information
06:01 EDTURBNUrban Outfitters downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information
July 30, 2015
10:32 EDTRAXOptions with increasing implied volatility
Subscribe for More Information
10:13 EDTRAXOptions with increasing implied volatility
Options with increasing implied volatility: ESPR SRPT CX RAX YY SPLK QIHU HFC OWW BBY
July 29, 2015
10:41 EDTRAXOptions with increasing implied volatility
Subscribe for More Information
10:27 EDTRAXOptions with decreasing implied volatility
Subscribe for More Information
10:00 EDTAROOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:47 EDTPDLIARIAD to receive $200M through syntehtic-royalty financing with PDL BioPharma
Subscribe for More Information
07:43 EDTPDLIARIAD to receive up to $200M through Iclusig synthetic-royalty financing with PDL BioPharma
ARIAD Pharmaceuticals (ARIA) announced that it will receive $100 million in cash – $50 million upon deal execution late yesterday and an additional $50 million in one year – through a synthetic-royalty financing from PDL BioPharma (PDLI) in exchange for paying PDL a mid-single-digit royalty on future sales of Iclusig until PDL receives a fixed internal rate of return. ARIAD also has an option, in its discretion, to receive up to an additional $100 million at any time between 6 and 12 months from the date of the agreement, in one or two tranches on comparable terms. ARIAD intends to use the base funds to conduct a front-line trial of brigatinib, its investigational ALK inhibitor, in patients with non-small cell lung cancer and to support brigatinib commercial readiness, as well as to continue its ongoing Iclusig initiatives. ARIAD is on track to complete enrollment in the pivotal ALTA trial of brigatinib in third quarter 2015, to file for approval in the U.S. next year, and subject to regulatory approval, to launch brigatinib by early 2017. Brigatinib has Breakthrough Designation from the U.S. Food and Drug Administration. “This financing allows us to accelerate initiation of the front-line trial of brigatinib and to ensure launch readiness as early as possible, while retaining strategic flexibility with respect to partnering and long-term commercialization of brigatinib,” said Harvey J. Berger, M.D., chairman and CEO of ARIAD. “We are confident based on the latest clinical data on brigatinib and other ALK‐inhibitors, that brigatinib may be an important new cancer medicine for patients with ALK+ lung cancer. With the funding provided by this royalty transaction, we expect to start the front-line trial by early next year, ahead of our expected filing for initial marketing approval of brigatinib in patients with refractory ALK+ NSCLC.”
06:04 EDTAROAeropostale downgraded to Sell from Neutral at UBS
Subscribe for More Information
July 28, 2015
14:41 EDTRAXHigh option volume stocks
Subscribe for More Information
13:26 EDTRAXRackspace volatility elevated into Q2 and outlook
Rackspace July weekly call option implied volatility is at 45, 7/14/15 weekly is at 77, September is at 48; compared to its 52-week range of 24 to 78, suggesting large near term price movement into the expected release of Q2 results on August 10.
07:29 EDTWPXSenate Banking, Housing & Urban Affairs Committee to hold a hearing
Subscribe for More Information
July 23, 2015
12:04 EDTRAXRackspace, Intel announce OpenStack collaboration
Subscribe for More Information
July 20, 2015
13:18 EDTAROOptions with increasing call volume
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use